Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK- positive non-small cell lung cancer (NSCLC).
Camidge D, Bang Y, Kwak E, Shaw A, Iafrate A, Maki R, Solomon B, Ou S, Salgia R, Wilner K, Costa D, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark J. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK- positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 2501-2501. DOI: 10.1200/jco.2011.29.15_suppl.2501.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalALK-positive non-small cell lung cancerCell lung cancerLung cancerPhase IPatientsCrizotinibCancer